Special Issue "Lipids, Health, and Diseases: The Interplay"

A special issue of Diseases (ISSN 2079-9721).

Deadline for manuscript submissions: closed (15 October 2021).

Special Issue Editors

Dr. Ronan Lordan
E-Mail Website
Guest Editor
Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Interests: cardiovascular diseases; inflammation; circadian rhythms; dietary supplements; nutraceuticals; aging; preventative medicine
Dr. Ioannis Zabetakis
E-Mail Website
Guest Editor
Department of Biological Sciences, University of Limerick, Limerick, Ireland
Interests: inflammation; polar lipids; nutritional status; functional foods
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Lipids are an incredibly diverse group of organic compounds that are structurally and biochemically involved in many physiological and cellular processes. They act as messengers in inflammation and immunity and are crucial in apoptosis, autophagy, and cell division. Over the last few decades, research has demonstrated that the role of lipids in health and diseases is of major importance and requires further research to advance therapeutics. The purpose of this Special Issue is to present current research that tackles the role of lipids in disease development and/or treatment. Current challenges to treat diseases such as cancer, neurological diseases, and cardiovascular diseases involve potent lipid mediators including eicosanoids and platelet-activating factors or changes of cellular lipid compositions. With the advances in ‘omics’ technologies and research, there is potential to discover novel lipid biomarkers and lipid mediators with pro-resolving effects, such as resolvins and protectins, and design new treatments.  

This Special Issue will provide an open access opportunity to publish research work and review articles related to recent advances in understanding the role of lipids in health and disease and will hopefully present new molecular insights for developing potential therapeutic treatments as well as better patient diagnostic and disease prevention strategies.

Dr. Ronan Lordan
Dr. Ioannis Zabetakis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Aging
  • Atherosclerosis
  • Biomarkers
  • Cancer
  • Cardiovascular diseases
  • Eicosanoids
  • Endocannabinoids
  • Lipid mediators
  • Lipidomics
  • Longevity
  • Metabolomics
  • Neurological diseases
  • Novel lipids
  • Phospholipids
  • Pro-resolving lipid mediators
  • Sphingolipids
  • Therapeutics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Reduced Skeletal Muscle Volume and Increased Skeletal Muscle Fat Deposition Characterize Diabetes in Individuals after Pancreatitis: A Magnetic Resonance Imaging Study
Diseases 2020, 8(3), 25; https://0-doi-org.brum.beds.ac.uk/10.3390/diseases8030025 - 01 Jul 2020
Cited by 1 | Viewed by 1297
Background: Skeletal muscle has been implicated in the pathogenesis of type 2 diabetes but it has never been investigated in diabetes after pancreatitis. The aim was to investigate the relationship between psoas muscle volume (PMV) and diabetes in individuals after pancreatitis, as well [...] Read more.
Background: Skeletal muscle has been implicated in the pathogenesis of type 2 diabetes but it has never been investigated in diabetes after pancreatitis. The aim was to investigate the relationship between psoas muscle volume (PMV) and diabetes in individuals after pancreatitis, as well as its associations with ectopic fat phenotypes and insulin traits. Methods: Individuals after an attack of pancreatitis and healthy individuals were studied in a cross-sectional fashion. All participants underwent magnetic resonance imaging, based on which PMV, skeletal muscle fat deposition (SMFD), as well as liver and intra-pancreatic fat depositions were derived. Fasting and postprandial blood samples were collected to calculate indices of insulin sensitivity and secretion. Linear regression analyses were conducted, adjusting for possible confounders (age, sex, body composition, comorbidities, use of insulin, and others). Results: A total of 153 participants were studied. PMV was significantly decreased in the diabetes group compared with healthy controls (β = −30.0, p = 0.034 in the most adjusted model). SMFD was significantly inversely associated with PMV (β = −3.1, p < 0.001 in the most adjusted model). The Matsuda index of insulin sensitivity was significantly directly associated with PMV (β = 1.6, p = 0.010 in the most adjusted model). Conclusions: Diabetes in individuals after pancreatitis is characterized by reduced PMV. Reduced PMV is associated with increased SMFD and decreased insulin sensitivity in individuals after pancreatitis. Full article
(This article belongs to the Special Issue Lipids, Health, and Diseases: The Interplay)
Show Figures

Figure 1

Back to TopTop